New drug combo shows promise for tough lung cancer
NCT ID NCT05519865
First seen Apr 22, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a certain type of advanced lung cancer (non-small cell lung cancer that is PD-L1 positive). The trial involved 118 adults who had not received prior treatment for their advanced cancer. The goal was to see if the combination could help control the disease by slowing its growth or shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.